Resultados da busca - Joel Jiang

  • Mostrando 1 - 10 resultados de 10
Refinar Resultados
  1. 1
    Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

    Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial por Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse, Gary Meininger, David R. Matthews

    Publicado em 2013
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression

    Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression por Saby George, Robert J. Motzer, Hans J. Hammers, Bruce G. Redman, Timothy M. Kuzel, Scott S. Tykodi, Elizabeth R. Plimack, Joel Jiang, Ian M. Waxman, Brian I. Rini

    Publicado em 2016
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

    Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes por Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger, David R. Matthews

    Publicado em 2014
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study

    Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study por Eugenio Mercuri, Francesco Muntoni, A. Nascimento Osorio, M. Tulinius, Filippo Buccella, Lauren P. Morgenroth, Heather Gordish‐Dressman, Joel Jiang, Panayiota Trifillis, Jin Zhu, Allan Kristensen, Claudio Santos, Erik Henricson, Craig M. McDonald, Isabelle Desguerre

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

    Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial por Jeffrey S. Weber, Geoff Gibney, Ryan J. Sullivan, Jeffrey A. Sosman, Craig L. Slingluff, Donald P. Lawrence, Theodore F. Logan, Lynn M. Schuchter, Suresh Nair, Leslie A. Fecher, Elizabeth I. Buchbinder, Elmer Berghorn, Mary Ruisi, George Kong, Joel Jiang, Christine E. Horak, F. Stephen Hodi

    Publicado em 2016
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis por Sandra P. D’Angelo, James Larkin, Jeffrey A. Sosman, Célèste Lebbé, Benjamin Brady, Bart Neyns, Henrik Schmidt, Jessica C. Hassel, F. Stephen Hodi, Paul Lorigan, Kerry J. Savage, Wilson H. Miller, Peter Mohr, Iván Márquez‐Rodas, J. Charles, Martin Kaatz, Mario Sznol, Jeffrey S. Weber, Alexander N. Shoushtari, Mary Ruisi, Joel Jiang, Jedd D. Wolchok

    Publicado em 2017
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 tri... por F. Stephen Hodi, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Christine E. Horak, Paul Gagnier, Joel Jiang, Jedd D. Wolchok, Michael A. Postow

    Publicado em 2016
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

    Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain por Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Karl D. Lewis, Christopher D. Lao, Michael A. Postow, Michael B. Atkins, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Reena Thomas, Ahmad A. Tarhini, Anna C. Pavlick, Joel Jiang, Alexandre Avila, Sheena Demelo, Kim Margolin

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

    Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy por Paolo A. Ascierto, Georgina V. Long, Caroline Robert, Benjamin Brady, Caroline Dutriaux, Anna Maria Di Giacomo, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Kerry J. Savage, Micaela Hernberg, Célèste Lebbé, J. Charles, Catalin Mihalcioiu, Vanna Chiarion‐Sileni, Cornelia Mauch, Francesco Cognetti, Lars Ny, Ana Arance, Inge Marie Svane, Dirk Schadendorf, Helen Gogas, Abdel Saci, Joel Jiang, Jasmine I. Rizzo, Victoria Atkinson

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients

    Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients por Craig M. McDonald, Francesco Muntoni, Vinay Penematsa, Joel Jiang, Allan Kristensen, Francesco Bibbiani, Elizabeth Goodwin, Heather Gordish‐Dressman, Lauren P. Morgenroth, Christian Werner, James Li, Richard Able, Panayiota Trifillis, M. Tulinius, Monique M. Ryan, Kelly Jones, N. Goemans, Craig Campbell, JK Mah, Kathryn Selby, B. Chabrol, Yann Péréon, Thomas Voït, Teresa Gidaro, Ulrike Schara, J. Kirschner, Yoram Nevo, GP Comi, Enrico Bertini, Elisa Mercuri, Jaume Colomer, A. Nascimento, Juan J. Vílchez, M. Tulinius, Thomas Sejersen, Francesco Muntoni, K. Bushby, Michela Guglieri

    Publicado em 2021
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: